NEW YORK (GenomeWeb) – Exosome Diagnostics said today that it has closed a $30 million Series C financing, led by Tiger Partners and Forbion Capital Partners.
Other participants included Blue Ridge Capital, NGN Capital, Arcus Ventures, b-to-v Partners, and CD Ventures among others.
Exosome Dx will use the funds to support what it says will be a rapid commercial expansion of its ExoDx Prostate (IntelliScore) test. The financing will also help sustain commercialization plans for other diagnostics in the oncology market and development of tests in other areas, such as neurodegenerative diseases, transplant rejection monitoring, and cardiology.
In addition, Exosome Dx said the funds will allow it to invest in the expansion of its companion diagnostics and instrumentation arms, including continued development of its Shahky point-of-care platform for exosomal protein biomarker detection.
Finally, the financing will also support investigations into new technologies, including methods to isolate disease-specific exosomes based on tissue type.